Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long-term data ...
Utilizamos cookies para asegurarnos de que tenga usted la mejor experiencia de navegación posible en el sitio web del Consejo. Ciertas cookies sirven para obtener estadísticas agregadas sobre las ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback